skip to main content
Idioma:
Mostrar Somente
Refinado por: Base de dados/Biblioteca: EZB Electronic Journals Library remover Nome da Publicação: Journal Of Clinical Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)
A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

Candamio Folgar, S. ; Méndez Méndez, C. ; Jorge Fernández, M. ; Romero Reinoso, C. ; Quintero-Aldana, G. ; Salgado Fernández, M. ; de la Cámara Gómez, J. ; Reboredo López, M. ; Ramos Vazquez, M. ; Lopez, R.

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.277-277 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study
How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study
Material Type:
Artigo 		Adicionar ao Meu Espaço

How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study

Chekerov, R. ; Oskay-Oezcelik, G. ; Otremba, B. ; Seipelt, G. ; Camara, O. ; Schmidt, M. ; Schmalfeldt, B. ; Lorsbach, E. ; Sehouli, J.

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16552-16552 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Dose-finding study of fixed dose rate (FDR) infusion of gemcitabine in combination with bevacizumab and escalating doses of irinotecan in patients with advanced gastrointestinal (GI) tumors
Dose-finding study of fixed dose rate (FDR) infusion of gemcitabine in combination with bevacizumab and escalating doses of irinotecan in patients with advanced gastrointestinal (GI) tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dose-finding study of fixed dose rate (FDR) infusion of gemcitabine in combination with bevacizumab and escalating doses of irinotecan in patients with advanced gastrointestinal (GI) tumors

Chopitea, A. ; Rodríguez, J. ; Viúdez, A. ; Viteri, S. ; De La Cámara, J. ; Reyna, C. ; Olier, C. ; Aramendía, J. M. ; García-Foncillas, J.

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.13068-13068 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
4
Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer
Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer

De La Cámara, J. ; Rodriguez, J. ; Rotellar, F. ; Viudez, A. ; García-Foncillas, J. ; Pardo, F. ; Gíl-Bazo, I. ; Chopitea, A. ; Martín-Algarra, S.

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3593-3593 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
5
Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer
Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer

De La Cámara, J. ; Rodriguez, J. ; Rotellar, F. ; Viudez, A. ; García-Foncillas, J. ; Pardo, F. ; Gíl-Bazo, I. ; Chopitea, A. ; Martín-Algarra, S.

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3593-3593 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
6
Escalating doses of hepatic arterial oxaliplatin in combination with docetaxel and capecitabine in patients with liver metastases from non-colorectal gastrointestinal malignancies
Escalating doses of hepatic arterial oxaliplatin in combination with docetaxel and capecitabine in patients with liver metastases from non-colorectal gastrointestinal malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Escalating doses of hepatic arterial oxaliplatin in combination with docetaxel and capecitabine in patients with liver metastases from non-colorectal gastrointestinal malignancies

De La Cruz, S. ; Rodriguez, J. ; De La Cámara, J. ; Nagore, G. ; Viteri, S. ; Reyna, C. ; Chopitea, A. ; Viúdez, A. ; Gúrpide, A. ; García-Foncillas, J.

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14110-14110 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
7
Bevacizumab in combination with continuous administration of capecitabine plus biweekly oxaliplatin: Preliminary results from the XELOX-AV trial
Bevacizumab in combination with continuous administration of capecitabine plus biweekly oxaliplatin: Preliminary results from the XELOX-AV trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bevacizumab in combination with continuous administration of capecitabine plus biweekly oxaliplatin: Preliminary results from the XELOX-AV trial

Echarri, M. ; Grávalos, C. ; Cámara, J. ; Ruiz, A. ; Garcia-Garcia, L. ; Hernández, M. ; Holgado, E. ; Gómez, C. ; Garcia, G. ; Cortes-Funes, H.

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.15074-15074 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Short induction docetaxel, doxorubicin, cisplatin and methotrexate followed by concurrent chemoradiation for nasopharyngeal carcinoma (NPC). A pilot study
Short induction docetaxel, doxorubicin, cisplatin and methotrexate followed by concurrent chemoradiation for nasopharyngeal carcinoma (NPC). A pilot study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Short induction docetaxel, doxorubicin, cisplatin and methotrexate followed by concurrent chemoradiation for nasopharyngeal carcinoma (NPC). A pilot study

Espinos Jimenez, J. ; Lopez-Picazo, J. M. ; Moreno Jimenez, M. ; Chopitea, A. ; de la Camara, J. ; de la Cruz, S. ; Garcia-Foncillas, J. ; Martin-Algarra, S. ; Perez Gracia, J. L. ; Gurpide Ayarra, A.

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.5590-5590 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
9
Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy
Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy

Fotopoulou, C. ; Braicu, E. I. ; Chekerov, R. ; Richter, R. ; Mentze, M. ; Pietzner, K. ; Pop, C. ; Camara, O. ; Oskay-Özcelik, G. ; Kuemmel, S. ; Blohmer, J. U. ; Lichtenegger, W. ; Sehouli, J.

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15507-e15507 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Correlation between the EGFR intron 1 CA dinucleotide repeat and skin toxicity in lung cancer patients treated with erlotinib
Correlation between the EGFR intron 1 CA dinucleotide repeat and skin toxicity in lung cancer patients treated with erlotinib
Material Type:
Artigo 		Adicionar ao Meu Espaço

Correlation between the EGFR intron 1 CA dinucleotide repeat and skin toxicity in lung cancer patients treated with erlotinib

Garcia-Donas, J. ; Leskelä, S. ; Sanchez, J. M. ; Camara, J. C. ; Rodriguez, N. ; Dhimes, P. ; Pinedo, F. ; Lopez, J. L. ; Jara, C. ; Rodriguez-Antona, C.

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.14001-14001 [Periódico revisado por pares]

Sem texto completo

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (12)

Refinar Meus Resultados

Data de Publicação 

De até
Refinar
  1. Antes de2004  (1)
  2. 2004Até2004  (8)
  3. 2005Até2005  (5)
  4. 2006Até2007  (8)
  5. Após 2007  (12)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.